Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
LA JOLLA, Calif., Nov. 27, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Victor Knopov, Ph.D. to its executive management team as Vice President, Pharmaceutical Development. Dr. Knopov joined Regulus from Nitto Denko Technical Corporation where he served as Director, Chemistry Manufacturing Control since 2010.
"Victor is a recognized expert in oligonucleotide drug delivery with over thirty years of experience," said Neil W. Gibson, Ph.D., Regulus' Chief Scientific Officer. "He will strengthen our accomplished management team and provide pharmaceutical development expertise as we advance our microRNA therapeutic programs toward the clinic."
"Regulus' mature product platform and established leadership in the microRNA field make joining the team an exciting opportunity for me," said Dr. Knopov. "I look forward to driving our microRNA therapeutic programs into clinical development."
Dr. Knopov has extensive knowledge of Chemistry, Manufacturing and Control, or CMC, development for various technology platforms including commercial production of enzymes, small anticancer liposomal products as well as advanced delivery systems for antisense, plasmids and siRNA based on lipids, polymer nanoparticles and conjugated systems. Prior to joining Nitto Denko Technical Corporation, from 2008 to 2010, Dr. Knopov was Chief Operating Officer at Diversified Bio-Medics, Inc. and an executive management consultant for CMC development at EnGene, Inc. and Marina Biotech, Inc. From 1997 to 2008, Dr. Knopov held various pharmaceutical manufacturing positions at Inex Pharmaceuticals Corporation where he led development for several pharmaceutical and biotech companies.
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.
For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SOURCE Regulus Therapeutics Inc.